Feasibility and safety profile of intranasal third-party allogeneic CD45RO(+)/RA(-) memory T cells: a phase I clinical trial (vRELEASE-I NCT06699758).
Delivering immune cells through the nose could offer a safer, more practical way to fight respiratory infections in vulnerable patients.
BACKGROUND: Respiratory viral infections remain a major global health challenge, particularly in immunocompromised populations. Although adoptive cell therapies using virus-experienced memory T lymphocytes have demonstrated safety and effectiveness when administered intravenously, the safety profile and feasibility of intranasal delivery of immun...
What the study was
- Study design
- Cohort study
- Population
- adults
- Category
- Other
- Maturity
- Exploratory
- Journal
- Frontiers in medicine
Why it surfaced
Score 7/10 [NOVEL_TREATMENT]: Cohort study (Journal Article) matched 'Sentinel'. Components — novelty:3/3, relevance:2/3, design:1/2, population:1/2. Confidence: high. Conservative scoring applied per v1.3 rubric.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.